Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.
OBJECTIVE
Most of the nanomedicines for treatment of multidrug-resistant cancer do not reach Phase III trials and many are terminated or withdrawn or are in an indeterminate state since long without any study results being presented. Extensive perusal of nanomedicine development research revealed that one of the critical aspects influencing clinical outcomes and which requires diligent scrutiny is selection process of nanodelivery system.


METHODS
Research papers and articles published on development of nanodelivery systems for treatment of multidrug-resistant cancer were analyzed. Observations and conclusions noted by these researchers which might shed some light on poor clinical performance of nanocarriers were collated and summarized under observation section. Further research articles were studied to find possible solutions which may be applied to these particular problems for resolving them. The inferences of these findings were composed in Result section.


RESULTS
Plausible solutions for the observed obstacles were noted as examples of novel formulations that can yield the following: better in vivo imaging, precise targeting and dosing of a specific site and specific cell type in a particular cancer, modulation of tumor surroundings, intonation of systemic effects and high reproducibility.


CONCLUSIONS
The angle of approach to the development of best nanosystem for a specific type of tumor needs to be spun around. Some of these changes can be brought about by individual scientists, some need to be established by collated efforts of scientists globally and some await advent of better technologies. Regardless of the stratagem, it can be said decisively that the schematics of development phase need rethinking.
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
P S
PS
Thakur
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
A M
AM
Khan
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
S
S
Talegaonkar
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
F J
FJ
Ahmad
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India. zeenatiqbal@jamiahamdard.ac.in.
Z
Z
Iqbal
D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*
Multidrug resistance; Nanodelivery system selection; Nanodelivery system targeting; Nanomedicine; Resistant cancer treatment